{"id":"W4417011124","doi":"10.1182/blood-2025-1993","title":"ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Discontinuation; Dosing; Cohort; Adverse effect; Clinical endpoint; Myeloid leukemia; Clinical trial; Cohort study; Tolerability","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001085744,0.0004870753,0.0007869143,0.0001757657,0.0002327152,0.0005653881,0.0003441468,0.0004810509,0.007753647],"category_scores_gemma":[0.0006940283,0.0001384397,0.0005668589,0.0002698219,0.0002640346,0.0005041704,0.0002030346,0.001311918,0.001170699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004378938,"about_ca_system_score_gemma":0.0004601804,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004163347,"about_ca_topic_score_gemma":0.0008003184,"domain_scores_codex":[0.9996834,0.0001095246,0.00002665393,0.00005740314,0.00007056756,0.0000524336],"domain_scores_gemma":[0.9993628,0.00009437766,0.0002458165,0.00005923896,0.00006736594,0.0001705113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5705674,0.02517906,0.0432142,0.001428233,0.00149384,0.0003583234,0.0001859354,0.00287601,0.1178187,0.0003182715,0.0196296,0.2169305],"study_design_scores_gemma":[0.1281029,0.5339637,0.2650995,0.0001034158,0.001391527,0.001550553,0.00008929766,0.003118845,0.03990017,0.0002900583,0.02630543,0.0000846004],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989988,0.001641293,0.0005490701,0.0002386518,0.00005622112,0.0004846707,0.002895859,0.0001418685,0.004004436],"genre_scores_gemma":[0.9903796,0.0004501673,0.0006438302,0.0002416128,0.00006744956,0.0003634827,0.003595954,0.00002562077,0.004232473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007753647,"threshold_uncertainty_score":0.02593851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009452666292112995,"score_gpt":0.2560672023998395,"score_spread":0.2466145361077265,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}